Natixis Investment Managers

SOFIAC is a company focused on enhancing the profitability and competitiveness of commercial and industrial sector businesses through energy efficiency initiatives. It specializes in the development, financing, and implementation of projects aimed at decarbonization and energy retrofitting. By employing an innovative investment model, SOFIAC enables clients to benefit from immediate savings generated by reduced energy consumption, allowing them to achieve their emission reduction goals without upfront costs. This approach supports Canadian businesses in lowering energy expenses while contributing to a sustainable energy transition.

Smart develops software designed to provide a range of pension services, including providing its own pension scheme and developing custom enterprise software for international markets. Their goal is to transform retirement, savings, and financial well-being for people of all ages all over the world.

Kiora Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing and commercializing innovative treatments for ophthalmic diseases. The company's lead product, KIO-301, is a molecular photoswitch designed to restore light perception and improve vision in patients suffering from inherited and age-related retinal degeneration, including conditions such as retinitis pigmentosa, choroideremia, and Stargardt disease. Kiora is also developing KIO-101, a next-generation non-steroidal, immuno-modulatory small molecule inhibitor targeting dihydroorotate dehydrogenase, aimed at minimizing off-target side effects while effectively managing immune responses. Additionally, Kiora is working on KIO-201, a modified form of hyaluronic acid intended to promote corneal wound healing. Through these products, Kiora Pharmaceuticals seeks to address significant unmet medical needs in the ophthalmic space.